The Difference Between Daily and Alternative Day Use of Icodextrin

Shanghai Jiao Tong University

Status and phase: Not yet enrolling; Phase 4

Conditions: Peritoneal Dialysis Solution Adverse Reaction

Treatments: Drug: Icodextrin Peritoneal Dialysis Solution

Study type: Interventional

Funder types: Other

Identifiers

NCT05943470

LY2023-083

Details and patient eligibility

About

Volume overload is an important cause of technical failure in peritoneal dialysis patients. Icodextrin can provide continuous ultrafiltration, which provides a new option for peritoneal dialysis patients.

However, icodextrin metabolites are known to accumulate to some extent in the body, resulting in less ultrafiltration with long-term icodextrin use comparing with newly use.

Therefore, the investigator hypothesized that a single dose of icodextrin would produce more ultrafiltration volume with the use of icodextrin dialysate on alternate days than with the use of icodextrin dialysate on daily uses.

Full description

1. Patients who met the inclusion criteria will be enrolled in this study.
2. Randomization.
3. Treatment A: daily icodextrin for 2 weeks. Treatment B: icodextrin is used every other day and original glucose-based dialysate is used every other day for a total of 2 weeks. The duration of icodextrin exchange is unchanged from the participants' original dialysate exchange regimen (typically, 8 to 14 hours). The interval is two weeks (the original dialysate was resumed). Participants would receive treatment A-B or B-A, depending on randomization.
4. Participants would record daily peritoneal ultrafiltration volume, long dwell ultrafiltration volume, dialysis prescription, urine volume, body weight, home blood pressure monitoring and complaints of discomfort.
5. Before the start of treatment (day 0), after the end of treatment period 1 (day14), at the end of washout period (day28), and at the end of treatment period 2 (day42), blood samples are collected for blood glucose, blood lipids, BNP, amylase, blood electrolytes, alkaline phosphatase. The participants' weight, blood pressure, dialysis prescription, daily ultrafiltration volume, urine volume, long dwell ultrafiltration volume and BCM measurement results would be recorded on the visit day. In the last 10 enrolled patients, blood samples would be collected for detection of icodextrin metabolites. After the end of treatment period 2, participants could choose the prescription of dialysate according to their own wishes and would be followed up for another 2 weeks.

Enrollment: 74 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. End-stage renal failure

  2. Patients with regular peritoneal dialysis in our center

  3. 18-75 years old

  4. Patients who currently use glucose dialysate for prolonged abdominals

  5. Sign informed consent

Exclusion criteria

• 1. The expected survival time is less than 3 months

  2. Known peritoneal dialysis tube dysfunction

  3. Peritonitis occurred within one month

  4. Known peritoneal effusion

  5. Known allergy to icodextrin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

74 participants in 2 patient groups

daily

Active Comparator group

Description:

daily use of one exchange of icodextin as long dwell

Treatment:

Drug: Icodextrin Peritoneal Dialysis Solution

alternative day

Experimental group

Description:

alternative day use of one exchange of icodextin as long dwell

Treatment:

Drug: Icodextrin Peritoneal Dialysis Solution